menu
    • menu

    Company profile for ExpreS2ion Biotechnologies

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ExpreS2ion has since its announcement on February 6th, 2020 of initiating a vaccine development programme against COVID-19 worked diligently to progress on its project, including setting up consortia of viral research and clinical vaccine experts, which together with our ExpreS2 protein production platform and our joint venture AdaptVac’s cVLP technology as core enabling technologies increase the likelihood of a unique vacci...
    ExpreS2ion has since its announcement on February 6th, 2020 of initiating a vaccine development programme against COVID-19 worked diligently to progress on its project, including setting up consortia of viral research and clinical vaccine experts, which together with our ExpreS2 protein production platform and our joint venture AdaptVac’s cVLP technology as core enabling technologies increase the likelihood of a unique vaccine with stronger and long lasting immune response. We are very proud of being part of this EU’s Horizon 2020 award, that supports our ambitious timeline of initiating clinical investigations within 12 months.”

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ExpreS2ion BiotechnologiesDenmark Flag
    Country
    Country
    Denmark
    Address
    Address
    SCION-DTU Science Park Agern Allé 1 DK-2970 Horsholm Denmark
    Telephone
    Telephone
    +45 2222 1019
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://expres2ionbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/expres2ion-biotechnologies/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/expres2ionb?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Evaxion and ExpreS²ion partner to develop new CMV vaccine
    Evaxion and ExpreS²ion partner to develop new CMV vaccine

    06 Dec 2022

    // PHARMACEUTICAL-TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/evaxion-expres%c2%b2ion-cmv-vaccine/

    PHARMACEUTICAL-TECHNOLOGY
    06 Dec 2022
    Share Share
    First subject vaccinated in COVID-19 Phase III clinical trial for ABNCoV2
    First subject vaccinated in COVID-19 Phase III clinical trial for ABNCoV2

    02 Sep 2022

    // CISION

    https://news.cision.com/expres2ion-biotechnologies/r/first-subject-vaccinated-in-covid-19-phase-iii-clinical-trial-for-abncov2-as-a-booster-vaccine,c3623296

    CISION
    02 Sep 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search